close read more

Our 5 therapeutic areas

To discover new treatments that improve patients’ lives, Servier invests an average of 25% of
its sales revenue (excl. generic medicines) in R&D. The Group focuses its research and development
efforts in therapeutic areas where needs are substantial.

    Neuropsychiatric diseases

    In the field of neurology, Servier focuses its research on neurodegenerative diseases. Servier targets proteinopathies, characterized by abnormal accumulation of certain proteins, such as Parkinson’s disease or rare diseases such as amyotrophic lateral sclerosis.

    Servier has thus signed a strategic partnership with Oncodesign for the research and development of inhibitors of LRRK2, which is considered a high-potential target for the treatment of patients with Parkinson’s disease.

    Similarly, a platform has been established to offer innovative therapeutic methods such as antisense oligonucleotides (ASO), to genetically correct the abnormal production of proteins at the root of certain neurodegenerative diseases.

    For autism, in partnership with Neurochlore, Servier is conducting two worldwide phase III studies for a drug candidate.